Leo H. Evart »

Crispr Therapeutics shares owned by Leo H. Evart

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Leo H. Evart from 13F filings

Historical chart of Leo H. Evart investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Leo H. Evart consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Leo H. Evart

Quarter filed Position value Share count Share price at filing
2026-03-31 $238 5 47.60

More positions owned by Leo H. Evart

Ishares 0-3 Month Treasury Bond Etf Uit Exchange Traded (SGOV)
Schwab U.s. Large-cap Growth Etf Uit Exchange Traded (SCHG)
Vanguard Total Bond Market Index Fund Etf Shares Uit Exchange Traded (BND)
Vanguard Intermediate-term Bond Index Fund Etf Shares Uit Exchange Traded (BIV)
Vanguard Value Index Fund Etf Shares Uit Exchange Traded (VTV)
Capital Group Dividend Value Etf Uit Exchange Traded (CGDV)
Vanguard Growth Index Fund Etf Shares Uit Exchange Traded (VUG)
Schwab International Equity Etf Uit Exchange Traded (SCHF)
Apple Common Stock (AAPL)
Vanguard Dividend Appreciation Index Fund Etf Shares Uit Exchange Traded (VIG)
Schwab U.s. Dividend Equity Etf Uit Exchange Traded (SCHD)
Vanguard Short-term Bondindex Fund Etf Shares Uit Exchange Traded (BSV)
Goldman Sachs Access Treasury 0-1 Year Etf Uit Exchange Traded (GBIL)
Schwab U.s. Mid-cap Etf Uit Exchange Traded (SCHM)
Vanguard Small-cap Indexfund Etf Shares Uit Exchange Traded (VB)

View all positions for Leo H. Evart

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital World Investors
State Street Corporation
T. Rowe Price Investment Management
Geode Capital Management
Vanguard Group
Susquehanna International
Sr One Capital Management
FMR
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
UBS Group
Two Sigma Investments

View all funds holding Crispr Therapeutics